ADC Therapeutics develops cancer treatments, led by ZYNLONTA for certain lymphomas, and is based in Epalinges, Switzerland. It last closed at $1.34 on Nov 17, up 6.32% on the day.
ADCT · as of the Nov 17 close · updated after every close
Downtrend
The stock is 13% below its 20 day and 3% below its 50 day average. It is 75% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 45). The nearest support is the Pivot at $1.33, and the nearest resistance the swing high (Sep 3) at $1.37.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 12.1%/day
Key levels
$4.9852 week high+271.6%
$2.35200 day average+75.4%
$1.5220 day average+13.4%
$1.42Pivot R1+6.0%
$1.3950 day average+3.7%
$1.37Swing high (Sep 3)+2.2%
$1.34Last close
$1.33Pivot−0.7%
$1.28100 day average−4.5%
$1.26Pivot S1−6.0%
$1.21Swing low (Jul 10)−9.7%
$0.7852 week low−41.8%
Indicators
RSI (14)
44.50
Middle of its range
Neutral
MACD
-0.01
Below its signal line
Bearish
Stochastic
9.0
Near the bottom of its range
Oversold
ADX (14)
21.4
Weak trend
Williams %R
-84.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-160.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−13.8%
Change over 10 sessions
Bearish
ATR (14)
$0.16
Typical daily range, 12.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 26.9%/day
Key levels
$4.9852 week high+271.6%
$2.35200 day average+75.4%
$1.5220 day average+13.4%
$1.42Pivot R1+6.0%
$1.3950 day average+3.7%
$1.37Swing high (Sep 3)+2.2%
$1.34Last close
$1.33Pivot−0.7%
$1.28100 day average−4.5%
$1.26Pivot S1−6.0%
$1.21Swing low (Jul 10)−9.7%
$0.7852 week low−41.8%
Indicators
RSI (14)
43.21
Middle of its range
Neutral
MACD
-0.25
Above its signal line
Bullish
Stochastic
51.8
Middle of its range
Neutral
ADX (14)
19.2
No clear trend
Williams %R
-57.0
Oversold below −80, overbought above −20
Neutral
CCI (20)
20.0
Oversold below −100, overbought above 100
Neutral
Rate of change
+25.7%
Change over 10 sessions
Bullish
ATR (14)
$0.36
Typical daily range, 26.9% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for ADCT
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ADCT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ADCT usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ADCT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ADCT is in one of them and how their past ADCT trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About ADC Therapeutics SA
ADC Therapeutics is a biopharmaceutical company based in Epalinges, Switzerland. It develops cancer treatments built on antibody drug conjugates, which link an antibody that targets cancer cells to a cell-killing payload. Its main product is ZYNLONTA, used for a type of lymphoma that has returned or stopped responding to earlier treatment, and partner Sobi handles much of its commercialization. Its customers include patients, the doctors who treat them, and the insurers and government programs that pay for care.